<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="154813">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02039791</url>
  </required_header>
  <id_info>
    <org_study_id>BT-IST-CC-072</org_study_id>
    <nct_id>NCT02039791</nct_id>
  </id_info>
  <brief_title>Study of Nimotuzumab in Combination With Neoadjuvant Chemotherapy for Cervical Cancer</brief_title>
  <official_title>Phase II Study of Nimotuzumab in Combination With Neoadjuvant Chemotherapy for Cervical Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biotech Pharmaceutical Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biotech Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <authority>China: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nimotuzumab is a humanized monoclonal antibody against epidermal growth factor receptor
      (EGFR). Clinical trials are ongoing globally to evaluate Nimotuzumab in different
      indications. Nimotuzumab has been approved to treat squamous cell carcinoma of head and neck
      (SCCHN), glioma and nasopharyngeal carcinoma in different countries. The clinical
      phaseⅡtrial is designed to assess the resection rate and pathological complete response of
      nimotuzumab plus carboplatin and paclitaxel in patients with cervical cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">August 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>resection rate</measure>
    <time_frame>the day right after surgery</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Pathological response rate</measure>
    <time_frame>the day right after surgery</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>objective response rate（ORR）</measure>
    <time_frame>The first seven weeks after the end of treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival  progression-free survival (PFS)</measure>
    <time_frame>Follow-up is for three consecutive years after surgery. Once every three months in the first year, and then once every six months in the second and third year.</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>Nimotuzumab plus chemoradiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Nimotuzumab</intervention_name>
    <description>200mg/w,weekly, 6 weeks</description>
    <arm_group_label>Nimotuzumab plus chemoradiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>AUC 6, d1，1 cycle/21d, 2 cycles</description>
    <arm_group_label>Nimotuzumab plus chemoradiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>175 mg/m2, d1
1 cycle/21d, 2 cycles.</description>
    <arm_group_label>Nimotuzumab plus chemoradiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age:18-70 years

          2. Histological confirmed Cervical squamous cell carcinoma

          3. FIGO Stage: IB2-IIIB

          4. Tumor lesions and stages are confirmed by the internal medicine, obstetrics and
             gynecology inspection, including a pelvic exam and abdominal and pelvic CT,.if
             necessary, laparoscopy, cystoscopy and pelvic MRI examination will be taken.

          5. At least one lesions can be measured

          6. No previous therapy

          7. ECOG performance status 0-2

          8. Life expectancy of more than 6 months

          9. Normal hematology:Haemoglobin≥90g/L,white blood cell(WBC)≥4×109/L Absolute neutrophil
             count≥1.5×109/L,platelet count≥100×109/L, normal renal function: serum
             creatinine&lt;1.5mg/dl or creatinine clearance rate&gt;60ml/min；normal liver
             function:TBIL≤1.5 ULN, AST and ALT≤1.5 ULN

         10. Without lung or heart disease

         11. Without active infection

         12. Signed informed consent and submit to the organization of research

        Exclusion Criteria:

          1. Severe systemic or uncontrolled disease, unfit for chemotherapy

          2. Neuropathy caused by any reason

          3. Psychiatric disease

          4. Other malignant tumor

          5. Bilateral renal pelvis and ureter hydrocephalus who can't be alleviated by ureteral
             stent or percutaneous nephrostomy, Abnormal serum creatinine level

          6. Infection and severe systemic disease

          7. Received other anti EGFR monoclonal antibody treatment

          8. Participation in other interventional clinical trials

          9. Allergic constitution or history of drug allergy

         10. Pregnant or breast-feeding or refused to take contraceptive method

         11. Poor compliance
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>yaping Zhu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai First People's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>yaping zhu</last_name>
    <phone>13371989235</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>youji Feng</last_name>
    <phone>13901790541</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanghai first people's hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>yaping zhu</last_name>
      <phone>13371989235</phone>
    </contact>
    <investigator>
      <last_name>yaping zhu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 16, 2014</lastchanged_date>
  <firstreceived_date>January 8, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
